CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer is a phase 2, interventional study registered as NCT06881537 by Shanghai Changzheng Hospital, with a registry enrolment figure of 15 participants, started 2024-06-01 and due to reach its primary completion in 2025-06-30. Interventions recorded: Capecitabine; Oxaliplatin; Bevacizumab; Tislelizumab. Conditions listed: Locally Recurrent Colorectal Cancer. Primary outcome: Objective response rate; R0 resection rate; Pathological complete response rate. Colorectal eligibility wording from the registry: "* Primary colorectal cancer underwent radical surgery, histologically confirmed as adenocarcinoma and achieved R0 resection, and postoperative adjuvant chemotherapy with Xelox or other first-line standard regimens". Sites: China. No results are recorded here; the registry entry is the source.